Table 1.
Biodistribution at 3 h of 1.0 μg of 99mTc-cMORF in CWR22 tumored BALB/c mice with and without the 72 h prior administration of 30 μg of MORF-B72.3, as well as the biodistribution at 72 h of 30 μg 111In labeled B72.3 radiolabeled by cDTPA and by p-SCN-benzyl-DTPA
| Organ | 99mTc-cMORF control (N=4) | 99mTc-cMORF/MORF- B72.3 pretargeted (N=4) | 111In-DTPA-B72.3 alone (N=4) | 111In-DTPA-benzyl- B72.3 alone (N=14) |
|---|---|---|---|---|
| %ID/g | ||||
| Liver | 0.20±0.03 | 0.76±0.16 | 15.72±2.38 | 6.25±1.16 |
| Heart | 0.04±0.01 | 0.56±0.13 | 1.72±0.35 | 2.74±0.21 |
| Kidney | 5.76±1.09 | 4.64±0.51 | 7.94±1.68 | 4.32±0.55 |
| Lung | 0.13±0.02 | 1.02±0.21 | 2.65±0.32 | 4.76±1.83 |
| Spleen | 0.07±0.01 | 0.42±0.04 | 6.42±0.60 | 3.57±0.36 |
| Muscle | 0.02±0.00 | 0.26±0.08 | 0.59±0.12 | 0.90±0.12 |
| Tumor | 0.12±0.02 | 1.81±0.18 | 4.28±0.56 | 4.71±0.73 |
| Salivary | 0.40±0.10 | 0.82±0.12 | 2.36±0.37 | 3.17±0.42 |
| Blood | 0.03±0.01 | 2.50±0.60 | 2.58±0.41 | 10.01±1.84 |
| %ID | ||||
| Liver | 0.28±0.04 | 1.27±0.20 | 21.51±2.21 | 9.61±1.81 |
| Heart | 0.01±0.00 | 0.09±0.02 | 0.24±0.02 | 0.37±0.05 |
| Kidney | 3.05±0.44 | 2.73±0.40 | 4.18±0.75 | 2.24±0.23 |
| Lung | 0.02±0.00 | 0.18±0.05 | 0.42±0.01 | 0.76±0.22 |
| Spleen | 0.01±0.00 | 0.07±0.01 | 0.86±0.28 | 0.52±0.10 |
| Stomach | 0.04±0.01 | 0.11±0.01 | 0.33±0.11 | 0.29±0.04 |
| Sm. Int. | 0.15±0.03 | 0.46±0.14 | 1.97±0.54 | 1.66±0.23 |
| Lg. Int. | 1.46±0.25 | 1.60±0.31 | 0.92±0.34 | 1.03±0.27 |
| Muscle | 0.19±0.03 | 2.56±0.76 | 5.51±1.03 | 8.67±1.11 |
| Tumor | 0.08±0.04 | 0.97±0.50 | 3.65±1.62 | 3.24±1.70 |
| Salivary | 0.08±0.03 | 0.17±0.04 | 0.44±0.06 | 0.53±0.09 |
| Blood | 0.05±0.01 | 4.39±1.02 | 4.18±0.55 | 16.91±2.96 |
| Weight (g) | ||||
| Tumor | 0.65±0.31 | 0.55±0.31 | 0.85±0.38 | 0.67±0.31 |
Results presented as %ID/g and %ID/organ as the mean ± one standard deviation